m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01722)
Name
N-Hydroxy-4-(4-methoxy-phenyl)-4-oxo-butyramide
Synonyms
CHEMBL366010; N-Hydroxy-4-(4-methoxy-phenyl)-4-oxo-butyramide
    Click to Show/Hide
Status
Investigative
Structure
Formula
C11H13NO4
InChI
1S/C11H13NO4/c1-16-9-4-2-8(3-5-9)10(13)6-7-11(14)12-15/h2-5,15H,6-7H2,1H3,(H,12,14)
InChIKey
YUAIIHPYXRCTLQ-UHFFFAOYSA-N
PubChem CID
44404461
TTD Drug ID
D08ZDD
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Matrix metalloproteinase-1 (MMP-1)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Matrix metalloproteinase-1 (MMP-1) is a therapeutic target for N-Hydroxy-4-(4-methoxy-phenyl)-4-oxo-butyramide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-Hydroxy-4-(4-methoxy-phenyl)-4-oxo-butyramide through regulating the expression of Matrix metalloproteinase-1 (MMP-1). [1], [2]
References
Ref 1 METTL3 involves the progression of osteoarthritis probably by affecting ECM degradation and regulating the inflammatory response. Life Sci. 2021 Aug 1;278:119528. doi: 10.1016/j.lfs.2021.119528. Epub 2021 Apr 21.
Ref 2 Receptor flexibility in de novo ligand design and docking. J Med Chem. 2005 Oct 20;48(21):6585-96. doi: 10.1021/jm050196j.